Medical Director

Jeffrey M. Melin, M.D., M.P.H.

*** **** **, *********** ** 19046

(H)215-***-****; (W) 484-***-****; (cell) 267-***-****

ablyh5@r.postjobfree.com

Summary Statement

Pharmaceutical physician with over 10 years experience in big pharma.

Expertise in strategic product differentiation, biologics and small

molecules, drug development, clinical trial design (Ph 1-4), translational

medicine, and due diligence for acquisition of novel pharmaceutical

compounds. Formal training in Clinical Immunology, Allergy, and

Rheumatology (triple-board certified) with strong emphasis on autoimmunity.

Professional Experience

2006 - Present Pfizer (formerly Wyeth) Pharmaceuticals

. Senior Director, Inflammation/Immunology Subspecialty Business Unit

o Enbrel Medical Lead for Medical Subcommittee, Rheumatoid

Arthritis, Safety (Global), and Product Medical Review Committee

(Benefit-Risk)

o Executive Leadership Team for Pfizer-Amgen Alliance (as US Lead

for Enbrel 2006-2009)

o Major focus on strategic product differentiation and design,

oversight, and direction of Phase IV clinical trials, overseeing

lifecycle plan for Enbrel

o Medical monitor for Enbrel Phase IV studies in psoriasis,

psoriatic arthritis

o Researching effects of TNF blockade in patients with metabolic

syndrome, cardiovascular disease, and Type II diabetes

o Team Lead evaluating company-sponsored global Investigator

Originated Proposals and affiliate Phase IV Studies (2006-09)

o Design and lead Advisory Boards for Enbrel, working with KOLS,

speaker training, oversight of key slide decks and

publications.

o Investigate new indications for anti-TNF therapies

o Identify and perform due diligence on potential compounds for

acquisition

o Pfizer Immunosafety Advisory Council Member

. Team Lead for Guidance on Hypersensitivity in Clinical

Trials Subteam

1999 - 2006 Merck & Co.

. 2005-2006: Director, Vaccines and Biologics, Merck Research Labs:

o Clinical Lead for developing 2nd generation HPV vaccine

(designed and initiated first 3 Phase I and II first-in-man

trials) to prevent cervical cancer

. 2002-2005: Director, Worldwide OTC Development, J&J/Merck, Merck

Research Labs:

o Clinical Lead for MEVACOR Rx-to-OTC Switch; expertise in statins

(simvastatin, lovastatin) and cardiovascular disease

. 1999-2002: Director, Medical Services, US Human Health: Coxibs (VIOXX,

ARCOXIA)

1987 - 1999 Jeffrey M. Melin, MD, PC (Private Practice) Philadelphia, PA

Allergy and Clinical Immunology, Rheumatology; Section Chief for A&I at

Episcopal Hospital (1987-1999) and Albert Einstein Medical Center; Asst

Clinical Professor of Medicine, Section of Rheumatology, Dept. of Medicine,

Temple University School of Medicine

1999 Medical Director, Fornance Clinical Trials (a startup division

of Fornance Physician Services, Inc. Norristown, PA);

. Conceived of a clinical trials division and wrote the

business plan

1994. CEO and Founder of World Square Corporation

. One of the first commercial marketplaces to sell on-line

merchandise.

. Sold 1996 to private entity

Education

1975-1977 Lehigh University Bethelem, PA

BA-Premedical Science (6-year accelerated BA/MD Program

together with Medical College of PA)

1977- 1981 Medical College of PA Philadelphia, PA

MD

2004-2006 Johns Hopkins Bloomberg School of Public Health

Baltimore, MD

MPH (Masters Degree in Public Health)

1. Inducted into Johns Hopkins Public Health Honorary Society

(Alpha Omega Alpha) based on merit

2008-present MBA Program

University of Massachusetts Amherst, MA

Post-Graduate Education

1981-1984 Temple University Hospital Philadelphia,

PA

. Internal Medicine Residency

1984-1987 Yale University School of Medicine New

Haven, CT

. Clinical Immunology Fellowship

. Rheumatology Fellowship

Professional lICENCES

PA: MD 028826E (active)

Inactive: NJ, CT

Professional memberships

Fellow, American College of Rheumatology (FACR)

Fellow, American College of Physicians (FACP)

Member, Delta Omega, Alpha Chapter Honorary Public Health Society (elected

to membership)

Selected Publications

Papers

1. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A

Improvements in patient-reported outcomes, symptoms of depression and

anxiety, and their association with clinical remission among patients

with moderate-to-severe active early rheumatoid arthritis Accepted to

Rheumatology 2010

2. Joyce AT, Smith P, Khandker R, Melin JM, and Singh A. Hidden Cost of

Rheumatoid Arthritis (RA): Estimating Cost of Comorbid Cardiovascular

Disease and Depression Among Patients with RA J Rheum 2009;36:743-752.

3. Brass, E.P., Allen S.E., Melin J.M. Potential impact on cardiovascular

public health of over-the-counter statin availability. Am J Cardiol.

2006;97:851-856.

4. Wortmann RL, Tipping RW, Levine JG, and Melin JM. Frequency of Myopathy

in Patients Receiving Lovastatin. Am J Cardiol. 2005; Apr 15; 95(8): 983-

985.

5. Nag SS, Pearson TA, Ma L, Landsman PB, Cimino A, Vickers FF, Alexander

CM, Melin JM. Estimating cholesterol treatment rates among individuals

with multiple risk factors and without coronary heart disease. Am J

Cardiol. 2005 Apr 1; 95(7):862-4.

6. Melin JM, Struble WE, Tipping R, Reynolds J, Vassil TC, Levy SJ,

Petrohoy TM, Midgette P, Hemwall EL, Levine JG, and Irvin JD. A Consumer

Use Study of Over-the-Counter Lovastatin (CUSTOM) Am J Cardiol

2004;94:1243-1248.

7. Hochberg M, Melin JM, and Reicin A. Cox-2 Inhibitors and Fracture

Healing: An Argument Against Such an Effect. Letter to the Editor.

JBMR 2003 March 18(3):583.

8. Sperling R, Braunstein N, Melin J, and Reicin A. Cyclooxygenase 2

inhibitors and thrombogenicity production: comment on the article by

Crofford et al. Arthritis & Rheum. 2001(May);44(5):1229-1230.

Abstracts and Posters

1. Strohal R, Puig L, Robertson D, Estojak J, Pedersen R, Melin J,

Freundlich B, Molta CT. Efficacy and safety of etanercept for the

treatment of moderate-to-severe psoriasis when used with adjunctive

topical therapy as needed: The PRISTINE Trial. European Society for

Dermatological Research. Sept 8-11, 2010 Helsinki Finland. Poster

2. Puig L, Strohal R, Robertson D, Estojak J, Pedersen R, Szumski A,

Freundlich B, Molta CT, Melin JM Baseline cardiometabolic

characteristics of moderate-to-severe plaque psoriasis subjects in the

PRISTINE trial J Invest Derm (European Society for Dermatological

Research) Abstract 252; Poster 408. 2010

3. Combe B, Mortensen E, Baumgartner S, Wajdula J, Robertson D,

Pedersen R, Freundlich B, Melin J Gastrointestinal perforations in

rheumatoid arthritis subjects treated with etanercept. Ann Rheum Disease

(EULAR 2010 June Rome, Italy) Abstract No. AB0310

4. Joly P, Kirkham B, Robertson D, Pedersen R, Molta B, Freundlich B, Melin

J. Influence of body mass index (BMI) on efficacy of etanercept in

psoriasis: The PRESTA Study. Abstract and Poster presented at the 28th

Fall Clinical Dermatology Conference, Las Vegas NV 15-18 Oct 2009.

5. Joly P, Kirkham B, Robertson D, Pedersen R, Molta B, Freundlich B, Melin

J. Influence of body mass index (BMI) on efficacy of etanercept in

psoriasis: The PRESTA Study. Abstract and Poster presented at the 2nd

World Psoriasis and Psoriatic Arthritis Conference. June 25-27, 2009

Stockholm, Sweden

6. Melin JM, Struble WE, Tipping R, Vassil TC, Reynolds J, Levy SJ, Irvin

JD. The CUSTOM Study: A Consumer Use Study of OTC Mevacor. The SE

National Lipid Association Meeting Aug 6-8, 2004 Orlando, FL

7. Nag S, Ma L., Landsman P, Vickers FF, Alexander CM, and Melin JM.

Estimating Lipid Treatment Rates Among Individuals with Multiple Risk

Factors. Circulation 2004;109:19

Merck Manuals Chapters Edited and Updated

. Chapter 131. Immunology of Aging (Merck Manual for Geriatrics) (2005)

. Chapter 53. Vasculitic Syndromes (Merck Manual for Geriatrics) (2005)

Date: June 21, 2010

Contact this candidate